Claus Bendtsen at AstraZeneca reveals how AI can be used to improve our understanding of disease, to help identify the causes of conditions and aid in drug discovery.

Join us as we discuss the latest data from the literature and application studies where diffusional sizing (MDS) is used to assess a variety of protein interactions – even of difficult targets.

A pharmaceutical target has been identified by Duke University that, when activated, can reverse bone degradation caused by osteoporosis.

A study has discovered the regulating process behind cell autophagy which could aid in the development of neurodegenerative disease treatments.

A new drug target for treating glioblastoma has been identified from a cellular pathway found to contribute to the spread of glioma stem cells.